Navigation Links
Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
Date:11/6/2008

ialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets Trp-p8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, the efficacy of PROVENGE or sipuleucel-T, the company's lead product candidate to treat men suffering from prostate cancer, the efficacy of NEUVENGE or lapuleucel-T, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials for PROVENGE or NEUVENGE will not support approval for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the results of a clinical trial for PROVENGE, NEUVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and a
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
7. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
8. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
9. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
10. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... , April 21, 2015 The non-invasive & minimally invasive cardiac output monitoring ... 2019. Geographically, Europe is segmented as Germany ... France and Rest of Europe (RoE). ... non-invasive & minimally invasive cardiac output monitoring devices market around 35.2% in 2014 followed ... Netherlands , Sweden , Poland ...
(Date:4/21/2015)... England , April 21, 2015 ... Queen,s Award for Enterprise, having more than doubled its ... Oxford PharmaGenesis today celebrates winning the Queen,s Award ... local employer is the world,s first HealthScience Communications consultancy, ... in areas of patient need. Having more than doubled ...
(Date:4/21/2015)... According to a new ... Cell, Blood, Gene Therapy), Product (Instruments, Services, Kits, ... Residual Contamination, Adventitious Agents) - Global Forecast to ... Testing Market was valued at $1,758.69 Million in ... a CAGR of 12.23% to reach $3,130.85 Million ...
Breaking Medicine Technology:European Non-invasive and Minimally Invasive Cardiac Output Monitoring Devices Market by Type, by End-User - Forecast to 2019 2European Non-invasive and Minimally Invasive Cardiac Output Monitoring Devices Market by Type, by End-User - Forecast to 2019 3Queen's Award Crowns Achievements of Local Consultancy 2Queen's Award Crowns Achievements of Local Consultancy 3Queen's Award Crowns Achievements of Local Consultancy 4Queen's Award Crowns Achievements of Local Consultancy 5Biologics Safety Testing Market Worth $3,130.85 Million by 2019 2Biologics Safety Testing Market Worth $3,130.85 Million by 2019 3Biologics Safety Testing Market Worth $3,130.85 Million by 2019 4
... YORK, Dec. 15, 2011  New York University and the ... they have appointed Theodore (Ted) Rappaport, 51, to lead ... Rappaport, currently the William and Bettye ... at Austin (UTA), is a leading educator and entrepreneur ...
... 15, 2011  Today, the Consumer Healthcare Products Association (CHPA), announced ... Five Moms campaign to raise awareness of ... of two teenage boys and a high school math teacher ... the dangers of substance abuse. Millions of ...
Cached Medicine Technology:Wireless Engineering Pioneer Joins NYU-Poly and NYU 2Wireless Engineering Pioneer Joins NYU-Poly and NYU 3Wireless Engineering Pioneer Joins NYU-Poly and NYU 4CHPA's Five Moms Campaign to Stop Medicine Abuse Welcomes New Mom Tammy Walsh 2CHPA's Five Moms Campaign to Stop Medicine Abuse Welcomes New Mom Tammy Walsh 3
(Date:4/21/2015)... WA (PRWEB) April 21, 2015 ... Practice Edition 2 for otolaryngologists, bringing the most ... the healthcare community. Otolaryngologists can now experience ... by a trusted source in the industry, Lyft, ... integration with leading EHRs. , “Lyft is very ...
(Date:4/21/2015)... 2015 QuickMedical, a veteran-owned leader ... now represents Schiller America's line of ... Tests, and Vital Signs Monitors, among many other ... a global leader in the development and production ... in close cooperation with the world's leading physicians ...
(Date:4/21/2015)... April 21, 2015 On April 8th, ... EcoLuxe Lounge at the world famous Avalon Hollywood. Organized ... product placement in TV and film, the EcoLuxe Lounge ... at many awards ceremonies and festivals throughout the year. ... of eco-friendly and socially conscious products and services, this ...
(Date:4/21/2015)... The 2015 Market Research Report on ... and in-depth study on the current state of ... a focus on the Chinese situation. , ... research are Cargill, Fbc Industries, Posy Pharmachem, Fuso, ... Lianyungang Mupro Fi, Yixing-Union, Debang Fine Chemical, Shuren ...
(Date:4/21/2015)... This year, in recognition of IAM, the Foundation ... publish a unique awareness campaign featuring real-life patients, affected ... of May and carry the message, "Be Inspired. Use ... was chosen to encourage the general public to learn ... support our mission of educating, inspiring and connecting all ...
Breaking Medicine News(10 mins):Health News:Lyft Expands Its Offerings to Include Dragon® Medical Practice Edition 2 for Otolaryngologists. 2Health News:QuickMedical Launches New Product Line: Schiller America 2Health News:QuickMedical Launches New Product Line: Schiller America 3Health News:Hollywood's Santana Dempsey and Choices Recovery South Bend Examine Victory over Personal Struggles 2Health News:Sodium Citrate Industry Global Key Manufacturers Analysis Report 2015-2020 2Health News:Sodium Citrate Industry Global Key Manufacturers Analysis Report 2015-2020 3Health News:May is Ichthyosis Awareness Month. Use Your Voice. 2
... LLC announces the pending release of its newest report, ... As a result of the March 9, 2009 reversal ... stem cell research, suppliers of stem cell related products are ... in the stem cell products market. In this report, BioInformatics, ...
... State University, discusses new research exploring weight discrimination against women in the workplace. , ... more information. , , , ... , , , , ... , , , , ...
... April 7 Did you know that April 16th is National Stress ... due? I don,t know, but spas can help. ISPA,s research shows ... relax and relieve or reduce stress. Here are some other facts ... 1/3 of Americans are living with extreme stress and nearly half ...
... Struggling with infertility issues on top of dealing with ... The troubled economy has slowed down, but biological clocks ... and men have biological clock realities. So, for ... they need some physical and financial help, there,s a ...
... Economic ActivitySACRAMENTO, Calif., April 7 California health plans ... economy, generating 130,000 jobs and $13.5 billion in economic ... by the California Association of Health Plans ... an outside consulting firm with expertise in health care ...
... Physicians for Human Rights responds to the publication of a ... that health professionals who participated in interrogations in CIA secret detention ... participated in torture. , ... Cambridge, MA (Vocus) April ...
Cached Medicine News:Health News:BioInformatics, LLC New Report - Capitalizing on New Opportunities for Stem Cell Products 2Health News:BioInformatics, LLC New Report - Capitalizing on New Opportunities for Stem Cell Products 3Health News:Weight discrimination could contribute to the glass ceiling effect for women, study finds 2Health News:Weight discrimination could contribute to the glass ceiling effect for women, study finds 3Health News:Weight discrimination could contribute to the glass ceiling effect for women, study finds 4Health News:Spas Add Years to Your Life 2Health News:Infertility Issues and No Insurance Do Not Necessarily Mean No Hope for Baby 2Health News:California Health Plans Vital to State's Economy 2Health News:In Wake of ICRC Report, Health Professionals Must Be Held Accountable for Torture 2Health News:In Wake of ICRC Report, Health Professionals Must Be Held Accountable for Torture 3
Used for drainage and retrograde pyelogram in pediatric patients. A stiffening stylet is included to aid in catheter placement. Supplied sterile in peel-open packages. Intended for one-time use....
... temporary internal drainage from the ... Supplied sterile in peel-open packages. ... Periodic evaluation is advised; polyurethane, ... not remain indwelling more than ...
... Used for urethral stenting ... drainage following hypospadias repair. ... to be stabilized in ... of sutures at the ...
... temporary internal drainage from ... the bladder. Supplied sterile ... for one-time use. CAUTION: ... C-Flex® and Sof-Flex® stents ...
Medicine Products: